CG Oncology, Inc. (NASDAQ:CGON) Stock Position Trimmed by Voya Investment Management LLC

Voya Investment Management LLC decreased its position in CG Oncology, Inc. (NASDAQ:CGON) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,163 shares of the company’s stock after selling 840 shares during the period. Voya Investment Management LLC’s holdings in CG Oncology were worth $406,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in CGON. NEOS Investment Management LLC increased its position in CG Oncology by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 8,329 shares of the company’s stock valued at $239,000 after acquiring an additional 817 shares during the period. Rhumbline Advisers increased its holdings in shares of CG Oncology by 2.2% during the fourth quarter. Rhumbline Advisers now owns 69,016 shares of the company’s stock valued at $1,979,000 after purchasing an additional 1,458 shares during the period. MetLife Investment Management LLC raised its stake in shares of CG Oncology by 7.0% during the fourth quarter. MetLife Investment Management LLC now owns 29,026 shares of the company’s stock valued at $832,000 after purchasing an additional 1,894 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in CG Oncology by 16.7% in the fourth quarter. New York State Common Retirement Fund now owns 13,996 shares of the company’s stock worth $401,000 after purchasing an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in CG Oncology in the 4th quarter valued at about $68,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.40% of the company’s stock.

CG Oncology Trading Down 1.6 %

NASDAQ CGON opened at $23.74 on Friday. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $40.47. The company has a market cap of $1.81 billion, a PE ratio of -16.72 and a beta of 1.08. The stock’s 50-day moving average price is $23.57 and its two-hundred day moving average price is $28.52.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. Research analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CGON shares. JPMorgan Chase & Co. assumed coverage on shares of CG Oncology in a research note on Friday, May 2nd. They issued an “overweight” rating and a $41.00 price target for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $55.00 price target on shares of CG Oncology in a research note on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. Scotiabank initiated coverage on CG Oncology in a research note on Wednesday, April 16th. They set a “sector perform” rating and a $23.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research report on Monday, April 28th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.70.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.